一覧に戻る

タイトル
  • Useful Oral Administration of Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) as Semaglutide (Rybelsus) for Type 2 Diabetes Mellitus (T2DM)
作成者
    • Bando, Hiroshi
権利情報
  • This is an open-access article distributed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
主題
  • Other Semaglutide
  • Other Rybelsus
  • Other Sodium N-(8-[2-hydroxybenzoyl] amino)
  • Other Peptide Innovation for Early Diabetes Treatment (PIONEER)
  • Other Semaglutide Treatment Effect in People with Obesity (STEP)
内容注記
  • Other As recommended pharmacological agents for type 2 diabetes mellitus (T2DM), Glucagon-Like Peptide 1 receptor agonist (GLP-1Ra) is highly evaluated for its various beneficial effects. Among them, semaglutide (Rybelsus) has been in focus for useful oral formation with useful oral hypoglycemic agent (OHA). Administration per os is possible due to the developed technique of absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. Clinical efficacy was shown by a series of Peptide Innovation for Early Diabetes Treatment (PIONEER) with enough weight reduction and decreased HbA1c. From the results of several PIONEER programs, oral semaglutide 14 mg/day had reduced HbA1c values by approximately 1.0-1.4%.
出版者 Asploro
日付
    Issued2022-02-22
言語
  • eng
資源タイプ journal article
出版タイプ VoR
資源識別子 URI http://repo.lib.tokushima-u.ac.jp/116814
関連
  • isIdenticalTo DOI https://doi.org/10.36502/2022/ASJBCCR.6260
収録誌情報
    • ISSN 2582-0370
      • Asploro Journal of Biomedical and Clinical Case Reports
      • 巻5 号1 開始ページ38 終了ページ41
ファイル
コンテンツ更新日時 2023-06-26